[Summary] An enterprise engaged in R&D and industrialization of recombinant prot
Beijing Sinocell Biotech Group Co., Ltd. is an innovative biopharmaceutical R&D company founded by Dr. Xie Liangzhi, an internationally renowned expert in biopharmaceutical R&D and industrialization, and a member of the expert panel for the Major New Drug Creation Program. The company focuses on the R&D and industrialization of biological drugs such as monoclonal antibodies, recombinant proteins, and vaccines. Since the establishment of the group's subsidiary Sinocell Engineering Co., Ltd. in 2002, the company has been committed to establishing a leading technology platform for biopharmaceutical R&D and production with advanced technical level and cost advantages through innovation in life sciences and engineering, to solve technical bottlenecks in drug R&D and production, and to provide high-quality biological drugs that are affordable to the public at an economic cost, thereby improving the accessibility of high-end biological drugs for patients in China and developing countries. At the same time, the company is committed to developing innovative biological drugs with differentiated competitive advantages in clinical practice, such as Best-in-Class or 'Me-better' products, to achieve the goal of entering developed markets in Europe and the United States with domestically developed and produced biological drugs, benefiting patients worldwide, and establishing an internationally leading biopharmaceutical brand. The company's management team has extensive experience in biological drug R&D and production. During his doctoral studies at the Massachusetts Institute of Technology, the founder Dr. Xie Liangzhi pioneered a stoichiometrically controlled fed-batch culture process for animal cells and increased antibody production from 50 mg/L to 2,400 mg/L in 1994, laying an important foundation for large-scale production of antibody drugs. After returning to China in 2002, he undertook several national '863' projects and major special projects for 'New Drug Creation'; led the team to establish an internationally first-class technology platform for biological drug R&D and industrialization, breaking through a series of key technologies and overcoming difficult drug production processes such as recombinant coagulation factor VIII, long-acting interferon-beta, and 14-valent HPV vaccines. The company's deputy general manager, Dr. Wang Yang, has over 20 years of experience in vaccine and antibody drug R&D and project management, and has led the quality analysis and establishment of quality standards for cervical cancer vaccines; she is an internationally renowned expert in biological drug quality control. On June 22, 2020, the company publicly issued shares for the first time and was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
What does Sinocell Engineering Co., Ltd. require? Who is Sinocell Engineering hiring? Sinocell Engineering recruitment: 销售类占比最多占64.3%，其次是医疗卫生/美容保健类占35.7%. What education can get in at Sinocell Engineering? 大专占比最多占61.3%，其次是本科占21%. High education required at Sinocell Engineering? 硕士占12.6%，博士占3.1%. Work experience required at Sinocell Engineering? 不限占比最多占38.1%，其次是1-3年占31%. Where are the job locations at Sinocell Engineering? 北京占比最多占29.1%，其次是武汉占3.7%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
